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Abstract. – OBJECTIVE: The authors have 
sought to expound upon and shed a light on the 
rise of nootropics, which have gradually taken 
on a more and more relevant role in workplaces 
and academic settings. 
MATERIALS AND METHODS: Multidisciplinary 
databases have been delved into by entering the 
following keys: “nootropics”, “cognitive enhance-
ment”, “workplace”, “productivity”, “ethics”, “bio-
engineering”. In addition, a broad-ranging search 
has been undertaken on institutional websites in 
order to identify relevant analysis and recommen-
dations issued by international institutions and 
agencies. Papers and reports have been inde-
pendently pored over by each author. This search 
strategy has led to the identification of 988 sourc-
es but only 64 were considered appropriate for the 
purposes of the paper after being selected by at 
least 3 of the authors, independently.
RESULTS: The notion of an artificially en-
hanced work performance – carried out by the 
‘superworker’ – is particularly noteworthy and 
resonates with the conception of contempo-
rary work on so many different levels: the rising 
need and demands for higher degrees of flex-
ibility and productivity on the job, the implica-
tions of a ‘24/7’ society, where more and more 
services are available at any time, the ever great-
er emphasis on entrepreneurial spirit, individu-
al self-reliance and self-improvement, and last 
but not least, the impact of an ageing society on 
economic standards and performance. 
CONCLUSIONS: Moreover, it is worth men-
tioning that human enhancement technologies 
will predictably and increasingly go hand in hand 
with gene editing, bioengineering, cybernetics 
and nanotechnology. Applications are virtually 
boundless, and may ultimately affect all human 
traits (physical strength, endurance, vision, in-
telligence and even personality and mood). 
Key Words:
Nootropics, Human Enhancement, Productivity, 
Workplace, Bioengineering, Ethics.
Introduction
The use of therapeutic drugs for non-medical 
reasons as cognitive enhancers has been spreading 
and its risks seem to have become at least in part 
acceptable among students and certain groups of 
workers. Considering the ever more competitive 
nature of modern societies, which reverberates on 
workplaces as well, enhancers are reasonably ex-
pected to spread even more over time; nonetheless, 
long-term consequences arising from their becom-
ing mainstream “supplements”, for the purpose of 
boosting performance, are as yet unknown. Cog-
nitive enhancers, used by healthy individuals, are 
widely known as nootropics: drugs, supplements, 
and other substances that may improve cogni-
tive function, particularly executive functions, 
strengthening memory, creativity or even moti-
vation in healthy individuals who choose to use 
them in an effort to take their performances “to the 
next level”. The word “nootropic” was coined in 
1972 by a Romanian scientist, Corneliu Giurgea, 
who combined the Greek words for “mind” and 
“bending”1-3. The pharmaceutical substances and 
compounds known as ‘cognitive-enhancers’ can 
allegedly boost mental performance, the ability to 
focus and keep concentration4. In broader terms, 
such drugs are often claimed to heighten and foster 
motor capabilities, affective skills, (i.e., one’s abili-
ty to deal with anxiety stemming from performing 
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certain work tasks or eliciting feelings of trust and 
affiliation) and are available for clinical and thera-
peutic reasons5. 
Furthermore, stagnant economic conditions 
certainly play a role in incentivizing worker com-
petition, within which some may feel compelled to 
consider substances to enhance their productivity. 
In fact, the key factor accounting for nootropics 
use in the workplace is productivity, as measu-
red by the amount of work produced per working 
hour, i.e., one of the main drivers of long-term eco-
nomic growth and higher living standards6. As a 
matter of fact, since the crippling 2008 economic 
crisis, productivity has lagged behind pre-crisis 
levels, with little or no significant steady growth7. 
Productivity growth goes hand in hand with eco-
nomic growth and development; hence the recent 
slowdown in aggregate labour productivity in le-
ading economies has been widely characterized 
as a puzzle, even paradox. Still, viewing pharma-
cological enhancers as a relatively easy shortcut 
towards greater productivity entails significant 
medical and ethical challenges8.
Cognitive Enhancers Used Off-Label: 
What About Safety and Effectiveness?
It is worth noting, however, that no drugs are 
licensed by medical authorities to be recommend-
ed and prescribed as ‘cognitive enhancers’ as 
such. Thus, the definition ‘performance-enhanc-
ing drug’ is usually linked to the off-label use of 
drugs prescribed for specific medical conditions 
by healthy individuals, for the purposes of per-
formance enhancement; modafinil9, used for the 
treatment of narcolepsy, or methylphenidate10, 
for Attention Deficit Hyperactivity Disorder 
(ADHD), fall within that category. Users acquire 
such medicines on the internet, or through some-
one who does have a prescription. Such dynamics 
mark a cultural shift in drug abuse dynamics: they 
are in fact free of the stigma usually associated 
with street drugs while also appearing safer, al-
though there can be no certainty as to their actual 
composition and nature; potential dangers are not 
as clearly perceived, since the term “medicine” is 
associated with treatment and cure.
A Broad-Ranging (and Growing) Array of 
Substances: Amphetamines
Several pharmaceutical drugs which are com-
monly associated with cognitive enhancing (Ta-
ble I):
Amphetamines, which are stimulants used to 
treat ADHD or narcolepsy, heighten dopamine 
levels11. Adderall (trade name) is a mixture of am-
phetamine salts. It is reportedly used off-label for 
the purpose of increasing focus (among workers 
and students, in particular) or to get a “high” (a 
strong, pleasing feeling of euphoria, typical of 
recreational drugs)12. Users have shown a tenden-
cy towards polydrug use and at times, adulter-
ants such as caffeine and phentermine have been 
found added to the amphetamines13,14. Polydrug 
use, which involves countless substances that are 
extremely hard to identify and regulate, is a seri-
ous threat that is bound to grow as online illicit 
market avenues become ever more accessible. For 
that reason, some have called for more invest-
ments in toxicological and forensic analytical data 
facilities and better international coordination in 
order to tackle that issue15. As for the enhancing 
capabilities of amphetamines, a 2014 systematic 
review has found that low doses of amphetamine 
could potentially foster memory consolidation 
and retention of information in healthy youth, as 
well as enhance task saliency (motivation to per-
form a task) and execution of tedious tasks requir-
ing substantial effort16,17.
A Widely Used Central Nervous System 
Stimulant: Methylphenidate
Methylphenidate (marketed und  er the brand 
names Ritalin, Equasym, Concerta, Rubifenis 
and Medikinet) acts as a stimulant of the central 
nervous system (CNS)18; its main application is 
treating ADHD and narcolepsy. It raises levels of 
the neurotransmitters dopamine and norepineph-
rine19. At above optimal doses, methylphenidate 
reportedly causes off-target effects negatively af-
fecting learning skills20. Adverse side-effects are 
a cause for concern: the dopaminergic activity of 
methylphenidate may lead to euphoria and addic-
tion (its mode of dopaminergic action is similar to 
that of cocaine). Methylphenidate can reportedly 
exacerbate existing behavioral problems and cen-
tral nervous system disorders such as bipolar dis-
ease and psychosis; its peripheral effects should 
not be overlooked: higher adrenaline concentra-
tions in plasma may in fact cause or worsen heart 
problems. Hence, methylphenidate is contraindi-
cated for patients with high blood pressure, heart 
defects or a family history of heart problems21.
Atomoxetine Hydrochloride Greater 
Alertness and Focus at What Cost?
	≤ Atomoxetine hydrochloride is licensed for 
the treatment of ADHD in children of six years 
and older, in children over the age of six and in 
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Chemical  
name Drug Class
Brand  
name
Mechanism  
of action
Therapeutic 
indications Side effects
Amphetamine Stimulant Adderall
Dopamine reuptake 
inhibitor; dopamine 
releaser
ADHD*, 
Narcolepsy
Agitation, 
anxiety, bladder 
pain, depression, 
nervousness
Methylphenidate Stimulant
Ritalin, 
Equasym, 
Concerta, 
Rubifenis 
Medikinet
Dopamine and 
noradrenaline 
reuptake inhibitor, 
dopaminergic and 
noradrenergic 
activity stimulant
ADHD*, 
Narcolepsy
 Anxiety/
nervousness, 
insomnia , appetite 
loss, dry mouth, 
nausea,  
Atomoxetine Adrenergic agent Strattera
Selective 
noradrenaline 
reuptake inhibitor 
ADHD*, 
Narcolepsy
Nausea, vomiting, 
insomnia, tiredness, 
constipation, 
appetite loss, dry 
mouth, dizziness, 
drowsiness, 
Donepezil Acetylcholinesterase inhibitor Aricept
Cholinergic 
transmission 
enhancer
Alzheimer-related 
dementia
Insomnia, nausea.
diarrhea. muscle 
cramps.tiredness.
Galantamine Acetylcholinesterase inhibitor
Nivalin, 
Razadyne, 
Razadyne 
ER, 
Reminyl
Stimulator of 
availability of 
acetylcholine 
for synaptic 
transmission
Cognitive 
decline in mild 
to moderate 
Alzheimer’s 
disease
Nausea, vomiting, 
appetite loss, 
diarrhea, dizziness, 
drowsiness
Rivastigmine Acetylcholinesterase inhibitor Exelon
Cholinergic 
transmission 
enhancer
Cognitive 
decline in mild 
to moderate 
Alzheimer’s 
disease associated 
with Parkinson’s 
disease
Nausea, vomiting, 
appetite loss, 
dizziness, drowsiness 
diarrhea, weakness, 
Tacrine Acetylcholinesterase inhibitor Cognex
Cholinergic 
transmission 
enhancer
Alzheimer’s 
disease
Sleepiness, 
headache, dizziness 
nausea, vomiting, 
diarrhea
Memantine
N-methyl-d-aspartate 
(NMDA) receptor 
antagonist
Namenda
Current flow 
blockade through 
channels of 
N-methyl-d-
aspartate (NMDA)
Moderate-to-
severe Alzheimer’s 
disease
Psychosis, headache, 
constipation, 
dizziness, sleepiness, 
Latrepirdine Anti-histaminic Dimebon
N-methyl-d-
aspartate (NMDA) 
glutamate receptors 
modulator; 
L-type calcium 
channels blocker; 
neurotoxic beta-
amyloid proteins 
blocker
Alzheimer’s 
disease 
(discontinued) 
Huntington’s 
disease 
(discontinued)
Sleepiness, 
constipation, 
headache, dizziness, 
cough, depression.
Table I. Principal pharmacological active substances used as nootropics and performance enhancers, their mechanism of action, 
therapeutic indications and side effects.
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young adults. In adults, symptoms of ADHD that 
were pre-existing in childhood should be con-
firmed. Atomoxetine, a selective nor-adrenaline 
reuptake inhibitor, is licensed in the UK for the 
management of ADHD although its precise action 
mechanism in ADHD is unknown. It is a selec-
tive noradrenaline reuptake inhibitor, causing in-
creased levels of noradrenaline in the CNS and 
ensuing higher alertness, attention and focus. It 
is generally considered to present no addiction 
Chemical  
name Drug Class
Brand 
name
Mechanism  
of action
Therapeutic 
indications Side effects
Modafinil Eugeroics
Modalert, 
Vigil, 
Provigil, 
Modasomil 
and 
Modiodal.
Dopamine reuptake 
inhibitor
Sleepiness due 
to narcolepsy, 
obstructive sleep 
apnea, shift work 
sleep disorder
Insomnia, nausea, 
diarrhea, headache, 
dizziness
Armodafinil Eugeroics Nuvigil Dopamine reuptake inhibitor
Sleepiness due to 
obstructive sleep 
apnea, narcolepsy, 
shift work sleep 
disorder.
Pain, muscle 
weakness, bruising, 
severe tingling, skin 
mouth sores 
Piracetam Racetams Nootropil
Positive allosteric 
modulator of 
the α-amino-3-
hydroxy-5-methyl-
4-isoxazolepropionic 
acid (AMPA) 
receptor, cholinergic 
and glutamatergic 
neurotransmission 
modulator
Alzheimer’s disease, 
dementia, memory 
dysfunction, 
alcoholism, 
Raynaud’s 
phenomenon
Insomnia nervousness, 
depression mud Weight 
gain Drowsiness
Aniracetam Racetams
Draganon, 
Sarpul, 
Ampamet, 
Memodrin, 
Referan
Modulator of 
the α-amino-3-
hydroxy-5-methyl-
4-isoxazolepropionic 
acid (AMPA) 
receptor, cholinergic 
and glutamatergic 
neurotransmission 
modulator
Senile dementia 
following stroke; 
Alzheimer’s disease
Psychomotor agitation, 
anxiety, motor 
restlessness, insomnia 
or drowsiness, 
headache,
Oxiracetam Racetams Oxiracetam
Positive modulator 
of α-amino-3-
hydroxy-5-methyl-
4-isoxazolepropionic 
acid (AMPA) -sensitive 
glutamate receptors
Dementia, organic 
brain syndrome
Increased psychomotor 
excitability, sleep 
disorders.
Pramiracetam Racetams Pramistar Acetylcholine release stimulant
Memory and 
attention deficits 
in elderly with 
neurodegenerative 
and vascular 
dementias
Nervousness, headache
Phenylpiracetam Racetams Phenotropil Carphedon
Acetylcholine release 
stimulant within 
hippocampal cell
Anti-amnesic, 
antidepressant, 
anticonvulsant, 
anxiolytic
Headache, insomnia, 
irritability
Table I. (Continued). Principal pharmacological active substances used as nootropics and performance enhancers, their 
mechanism of action, therapeutic indications and side effects.
*ADHD: attention deficit, hyperactivity disorder.
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potential compared with methylphenidate, being 
devoid of any dopaminergic effect. Nevertheless, 
its adrenergic effect may lead to cardiotoxicity. It 
is therefore contraindicated in individuals with 
existing cardiac defects or heart problems. Stud-
ies have shown unwanted side effects associated 
with the use of atomoxetine in adults such as dry 
mouth (16-55%), decreased appetite (12-50%), in-
somnia (17-35%), nervousness (35%), constipation 
(7-20%), erectile dysfunction (5-11%), nausea (12-
40%), dizziness (6-15%), decreased libido (7%), 
sweating (5-20%), fatigue (16-25%), increased 
heart rate (17%), hypertension (10%), hot flashes 
(10%), depression (10%), and urinary problems 
(6-10%)22,23.
AChE Inhibitors and NMDA Receptor 
Antagonists
Donepezil hydrochloride is a second-genera-
tion acetylcholinesterase (AChE) inhibitor struc-
turally dissimilar from other established AChE 
inhibitors. Experimentally, donepezil inhibits 
AChE activity in human erythrocytes. Donepezil 
is licensed for the treatment of mild to moderately 
severe symptoms of Alzheimer-related demen-
tia24. Donepezil is a selective reversible cholines-
terase inhibitor in the CNS, leading to increased 
acetylcholine concentration and stimulation of 
muscarinic receptors. Studies in mice have also 
indicated an increase in hippocampal production 
of insulin-like growth factor I and a protective 
effect against neurodegeneration25. Donepezil’s 
cholinergic activity may result in side effects such 
as diarrhea, nausea, vomiting and effects on the 
central nervous system such as insomnia. Stud-
ies on the use of donepezil in healthy adults have 
shown improvement in perceptual learning and 
skill acquisition. However, recent findings in old-
er healthy individuals showed negative cognitive 
effects, such as a significant decrease in memory. 
The cognitive effects of donepezil are believed 
to depend on the user’s mental status, with pos-
itive effects being more likely to show up when 
the reduced cognitive performance is due to ex-
ternal aggravating factors, such as sleep depriva-
tion26. Studies have shown that donezepil, galan-
tamine, rivastigmine and other NMDA receptor 
antagonist such as memantine and antihistamine 
latrepirdine can foster neurite outgrowth to a sig-
nificant extent in an embryonic primary cortical 
culture system27. In fact, in a rodent model of ba-
socortical deterioration, donepezil has been able 
to induce cholinergic sprouting28. Moreover, do-
nepezil has been found to bind sigma1 receptors 
in addition to its main target, with high affinity 
at a low nanomolar range in vitro, acting as an 
effective sigma1 receptor agonist. Sigma1 recep-
tor ligands Pre-084 and 4-IBP, in fact, foster neu-
ritogenesis. Other compounds, including NMDA 
receptor antagonist memantine and antihistamine 
latrepirdine (dimebon), which also reportedly 
bind sigma1 receptors at its effective dose of mi-
cromolar range, have been observed to improve 
neurite outgrowth29. In addition to donepezil, oth-
er AChE inhibitors have been used as potential 
nootropcs, including tacrine, galantamine and 
rivastigmine, all of which can apparently height-
en the level of acetylcholine neurotransmitter via 
the inhibition of acetylcholine hydrolysis. N-me-
thyl-D-aspartate (NMDA) receptor antagonists 
including memantine (approved for the treatment 
of moderate to severe AD)30, which are aimed at 
suppressing excitotoxicity caused by β-amyloid 
and excitotoxic neuronal damage, preventing glu-
tamate-induced overstimulation, and lowering 
abnormal neurotransmitter-mediated activation 
of the receptors31. If transient low-level, nonpath-
ological, glutamate-mediated neuronal damage 
can occur in the brains of healthy individuals, 
it is possible that the neuroprotective effects of 
memantine might be able to counter the damag-
ing effects and enhance memory potential in such 
individuals. Further research is needed to clarify 
those points32. Memantine’s presumed neuropro-
tective effect may also raise N-acetyl aspartate 
(NAA) brain levels, i.e., a marker of density neu-
ronal and axonal viability and mitochondrial me-
tabolism. Although the function of NAA within 
axons in the white matter is still not fully known, 
its function might partly involve the synthesis of 
neurotransmitters. Memantine’s alleged neuro-
protective capabilities might be gauged by the va-
riations in NAA concentrations in brain tissue via 
magnetic resonance spectroscopy33. Clinical and 
pre-clinical research has pointed out that meman-
tine, at doses producing a steady-state plasma lev-
el of 0.5-1 mM, is well tolerated, and could even 
lead to some degree of cognitive enhancement34.  
Eugeroics: Fostering Wakefulness and 
Alertness
Eugeroics such as Modafinil/Armodafinil, also 
a central nervous system stimulant, foster wake-
fulness. Modafinil is known to interact with neu-
rotransmitters such as dopamine and norepineph-
rinets, although its exact action on the brain has 
not been fully figured out yet. It is an FDA-ap-
proved eugeroic which directly raises cortical cat-
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to simple vs. complex tasks in various youth seg-
ments.
Nootropics on the Job: 
a Double-Edged Sword
As for enhancers use in the workplace, there 
are specific professional categories more liable to 
use or abuse performance-enhancers on the job, 
among those:
Military personnel: modafinil has been made 
available to combat personnel in several coun-
tries, under medical supervision and clearly de-
fined circumstances.  
Militaries of several countries are known to 
have expressed interest in modafinil as an al-
ternative to amphetamine, traditionally used by 
troops to cope with sleep deprivation, such as 
during lengthy missions. The Foreign Legion 
used modafinil during certain covert operations, 
as conceded by the French government itself. The 
United Kingdom’s Ministry of Defense commis-
sioned research into modafinil from QinetiQ and 
spent £300,000 on one investigation40. In 2011, it 
was conceded by the Indian Air Force that modaf-
inil was part of “contingency plans”41.
In the United States military, modafinil has 
been approved for use on certain Air Force mis-
sions, and it is being investigated for other uses42. 
As of November 2012, modafinil is the only drug 
approved by the Air Force for the purpose of tack-
ling fatigue. Dextroamphetamine use is no longer 
approved43.
	≤ Transportation workers: in order to cope 
with long shifts, transport workers have been 
found to use amphetamines and other stimu-
lants44.
Workers Providing Emergency Services 
and Health Care
In the United States, Shift Work Sleep Disor-
der is a diagnostic category, with modafinil rec-
ognised as a medically approved treatment to 
promote alertness. Prescription in the EU was 
also possible for the condition Shift Work Sleep 
Disorder until the restriction imposed by the Eu-
ropean Medicines Agency (EMA) in 2011. A 2013 
survey45 has shown that about 15% to 20% of sur-
geons have used cognitive or mood enhancement 
drugs at least once during their lifetimes. This 
may be attributed to high workload and intense 
work-related and private stress. As found in a 
2012 randomized controlled trial by the Imperi-
al College London46, modafinil improved perfor-
mance on tests of higher cognitive function: those 
echolamine levels, indirectly upregulates cerebral 
serotonin, glutamate, orexin, and histamine lev-
els, and indirectly lowers cerebral gamma-ami-
no-butyric acid levels. Aside from its approved 
use for the treatment of somnolence, modafinil 
is reported to be widely used off-prescription 
for cognitive enhancement. There has been little 
consensus, however, as to the actual effectiveness 
and nature of the cognitive benefits of modafinil 
in healthy, non-sleep-deprived humans, despite 
its growing popularity35. 
Racetams
Racetams are a class of drugs that include noo-
tropics such as piracetam, aniracetam, oxirace-
tam, pramiracetam and phenylpiracetam. All such 
chemicals share a pyrrolidone nucleus. Piracetam 
in particular is a nootropic that has been used since 
the 1960s and is still considered to be a pioneer 
“smart drug”, popular among college students due 
to its availability in several dietary supplements. A 
derivative of the neurotransmitter γ-aminobutyric 
acid (GABA), piracetam has various physiological 
effects that are thought to arise from the improve-
ment of cell membrane fluidity36. From a neuronal 
standpoint, piracetam acts as a modulator of neu-
rotransmission in several transmitter systems (no-
tably cholinergic and glutamatergic); in addition 
to that, it may positively affect neuroplasticity 
thanks to its neuroprotective and anticonvulsant 
properties. From a vascular standpoint, piracetam 
appears to reduce erythrocyte adhesion to vas-
cular endothelium, hinder vasospasm, and favor 
microcirculation. Such wide-ranging physiologi-
cal effects have led to its use in a broad array of 
clinical indications. It is reportedly effective in the 
treatment of cognitive disorders and cortical myo-
clonus, vertigo, dyslexia, dementia, and sickle cell 
anaemia, although some studies37,38 have reported 
an adverse outcome in the treatment of a patient 
with a history of mental illness. 
A 2014 systematic review39 on youth popula-
tions has highlighted that modafinil appears to 
improve reaction time (p ≤ 0.04), logical reason-
ing (p ≤ 0.05) and problem-solving. Furthermore, 
methylphenidate appears to improve performance 
in novel tasks and attention-based tasks (p ≤ 0.05), 
while reducing planning latency in more complex 
tasks (p ≤ 0.05). Amphetamine has a potential 
to improve consolidation of information (0.02 ≥ 
p ≤ 0.05), resulting in better memory. Improved 
attention has been reported for all three types of 
prescription stimulants, despite a lack of consen-
sus on whether these improvements are limited 
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The American Medical Association has taken a 
stand on nootropics, particularly pharmaceutical 
“enhancers” in light of their widespread off-label 
use. Prescription drugs that are FDA-approved 
to treat attention-deficit hyperactivity disorder 
or narcolepsy are commonly associated with the 
off-label use by students and others seeking to 
boost memory, learning or other aspects of cog-
nition. Such use is associated with a variety of 
adverse mental health conditions and patterns of 
substance misuse. 
Provided that prescription stimulants un-
doubtedly entail risks, they do not necessarily 
make people smarter. As a matter of fact, avail-
able evidence defines the cognitive effects of 
prescription stimulants to be dose-dependent, 
highly variable among individuals, and like-
ly limited or modest, at best, in healthy users. 
Not enough conclusive data and information 
are available as to the patterns of dietary sup-
plements and herbal substances used for cog-
nitive enhancement. More than 100 substances 
from aminoacids to botanical preparations are 
advertised on websites as having the ability to 
enhance cognitive performance; nevertheless, 
their actual safety and effectiveness have not 
been systematically examined.
The new AMA policy acknowledges that avail-
able information is somewhat lacking and under-
scores the need for more research into the patterns 
of use, as well as risks and benefits, of dietary sup-
plements and herbal remedies being promoted for 
cognitive enhancement. The AMA will also urge 
the Federal Trade Commission to examine ad-
vertisements for dietary supplements and herbal 
remedies that claim cognitive enhancement to en-
sure that they are not misleading53. Furthermore, 
a 2018 discussion paper by the European Agency 
for Safety and Health at Work (EU-OSHA) adds to 
and broadens the scope of the analysis, citing the 
significance of the social and economic context 
and taking into account potential ‘trigger’ factors 
within the workplace and changes in working con-
ditions at large. It is worth making a connection 
with other future challenges and ‘emerging risks’ 
that EU-OSHA identified and discussed within 
its earlier Foresight (EU-OSHA, 2014) and other 
reports54. As for the broader social and economic 
context within which performance enhancers are 
used, the increase in precarious employment for-
ms more insecure, often not protected under stan-
dard labour rights and legislation, with low wages 
and at times subject to constant surveillance and 
monitoring. 
in the modafinil group worked more efficiently 
when solving working memory (F1.38 = 5.24, p 
= 0.028) and planning (F1.38 = 4.34, p = 0.04) 
problems, were less-impulsive decision makers 
(F1.37 = 6.76, p = 0.01), and were more able to 
flexibly redirect their attention (F1.38 = 4.64, p 
= 0.038). By contrast, no improvement has been 
observed in tests of clinical psychomotor perfor-
mance. The trial’s findings show that stressed-out 
doctors might benefit from pharmacological en-
hancement in circumstances requiring efficient 
information processing, flexible thinking, and 
decision-making under time constraints. No im-
provement, however, is likely to be seen in the 
performance of basic procedural tasks.
	≤ Other groups of workers in high-pressure, 
competitive environments, such as financial trad-
ers, academics and lawyers, have been linked to 
performance-enhancing drugs use for various 
reasons: to keep up with professional demands, to 
heighten productivity rates or to get over jetlag47.
Can Performance Enhancing Drugs 
Really Yield a Net Benefit? As Doubts 
Linger, AMA and EU-OSHA Weigh in
When analyzing the effects of the drugs, it 
should be borne in mind that despite possible im-
provements in the execution of some cognitive 
tasks, with at least temporarily better productivity, 
different work-related aspects might be adversely 
affected by the use of enhancers. Overconfidence 
in one’s abilities stemming from the use of perfor-
mance-enhancers could in fact penalize teamwork, 
potentially undermining group cohesion and coop-
eration. Furthermore, overestimating one’s abilities 
on account of drug use may prove risky in terms of 
decision making under critical conditions48,49; after 
all, even “physical enhancement” practices, i.e., co-
smetic surgical interventions are often ethically and 
morally controversial, particularly when aimed at 
minors, given the daunting difficulties in objectively 
defining their best interest. It is extremely hard to 
arrive at a universally acceptable risk-benefit analy-
sis, when it comes to enhancement50. As a matter of 
fact, performance-enhancing drugs have a potential 
to affect work performance, as well as relationships 
with others and the success and quality of teamwork. 
A trade-off between better concentration skills and 
a decrease in sociability would only be acceptable 
when individuals work alone; it is however undesir-
able within the context of teamwork51.
In Forbes et al52 various nutrients and dietary 
supplements found no convincing evidence of im-
provements in cognitive performance. 
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generation, most life-changing conditions such as 
hereditary diseases, paralysis, organ failure will 
become curable and reversible thanks to the syner-
gy and interaction of multidisciplinary engineering 
fields within the realm of bioengineering. Genet-
ical transformation for the purpose of generating 
new forms of treatment has already been success-
fully achieved by bioengineers. On the other hand, 
this technological enhancement will profoundly 
affect society, because of the “interruption” it will 
bring about in the human being. Rather than pro-
ducing altered and desired characteristics, bioen-
gineering/biomedical efforts focus on gene ther-
apy: therapeutic applications specifically targeted 
to inherited diseases. Gene-editing and bioengi-
neering could therefore open up new avenues with 
almost limitless potential. This hot topic has also 
been discussed from a medical ethics perspective 
in different countries such as Italy, where the code 
of Medical ethics has been updated and is currently 
more closely focused on medical enhancement and 
cosmetic medicine. In its current version, the Code 
states that medical doctors being asked to provide 
or prescribe cognitive enhancers must always act 
in adherence to the highest standards of respect 
and protection for human dignity, identity, integ-
rity, and the inherent genetic traits, abiding by the 
principles of proportionality and precaution61.
When “Curing” Gets Conflated with 
“Improving”, Daunting Ethical 
Challenges Come to the Fore
Along with the foreseeable clinical and ther-
apeutic applications, breakthroughs in bioengi-
neering will likely not only be aimed at “curing” 
disease but at altering and enhancing human per-
formance in otherwise perfectly healthy individ-
uals as well. Gene editing techniques generally 
involve proteins that cut DNA, such as those em-
ployed in CRISPR-Cas962, transcription activa-
tor-like effector nucleases (TALENs) and zinc-fin-
ger nucleases63,64. Recent research has confirmed 
that the most commonly used Cas enzyme, Cas9, 
comes from Streptococcus pyogenes, which has 
proven viable in mouse and human cells in 201365. 
The CRISPR molecule is programmed to search 
for a specific nucleotide sequence among the 3 
billion in the human genome. CRISPR then un-
winds the coils of DNA coils and “cleaves” the 
sequence out of the strand. When carried out in 
an embryonic germ line cell, egg or a sperm cells, 
gene “edits” will become part of the genetic code 
that is passed on to future generations. Nonethe-
less, errors arising from “overediting” have been 
Conclusions: Changing Working 
Conditions Constitute a Sea-Change
Recent research provides an insight into the 
changing nature of working conditions, partic-
ularly those associated with the ‘gig economy’. 
Although no studies have been carried out to 
investigate a direct relationship between perfor-
mance-enhancers and changing working condi-
tions, there is some indication in Moscone et al55. 
In this large-scale study, when workers move into 
more precarious working conditions, that transi-
tion may be linked to poorer mental health and an 
increase in prescriptions of psychotropic drugs. It 
would be certainly useful to conduct similar stud-
ies in relation to performance-enhancing drugs. 
Undoubtedly, the use of performance-enhancers 
may be perceived by workers as a way to cope 
with monotony or to keep up with the demands of 
machine and electronically-paced work; besides, 
the lack of social and individual control over work 
conditions, the growing degree of fragmentation 
of working times and spaces, and the difficulty in 
striking a balance between gainful employment 
and private life all pose a real threat to the work-
ers’ livelihoods and even mental health. In fact, 
although pharmacological enhancers can increase 
and sharpen cognitive capabilities in healthy in-
dividuals (albeit experimental and clinical stud-
ies have so far proven relatively modest over-
all effects, likely due to the degree of response 
variability across as well as within individuals), 
they can produce side effects in body systems 
other than the brain. Rivastigmine, for instance, 
in healthy elderly subjects can improve learning 
on a motor level and the ability to make associa-
tions between symbols and digits; yet, at the same 
time, its intake has been found to negatively affect 
skills related to verbal and visual episodic mem-
ory56. Likewise, bromocriptine, a dopamine ago-
nist, can enhance spatial working memory while 
lowering probabilistic reversal learning skills in 
young individuals57,58. 
Smart Drugs Soon to be Outdated?
Pharmacological performance and cognitive en-
hancers may relatively soon be replaced by human 
biological enhancement technologies (HBETs): 
the augmentation of human capacities by biologi-
cal manipulation59. Engineering applied to biology 
has made giant strides over the past decades, be-
coming one of the fastest-growing scientific fields 
of the 21th century and possibly leading to a novel 
conception of the right to enjoy good health60. It 
is in fact reasonable to predict that over the next 
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observed with targeting linked to the guide RNA 
used to target the deletions66. Thus, non-specif-
ic and unintended genetic alterations may occur 
through engineered nuclease technologies such 
as CRISPR-Cas9. It is the very presence of such 
“off-target repeats” that calls for extreme caution 
and stresses the need for better regulation before 
techniques such as CRISPR can have acceptably 
safe clinical applications67,68. Given how high 
the stakes are, scientists, regulators and society 
need to strike an ethically acceptable balance be-
tween the vast potential good that undoubtedly 
can be achieved through the new techniques and 
the risks of doing it just because it can be done69. 
Science needs to move fast, which does not mean 
hastily. It is essential to map out a tenable ethical 
and moral path ahead, defining which techniques 
and applications ought to be developed, how far 
and to where. Scientists and engineers have been 
striving towards nothing less than our common 
futures and core identities as human beings70,71. 
Yet, guiding the creation of that future is the right, 
duty and responsibility of all parts of society and 
of the human race72; such an endeavor cannot be 
exclusively entrusted to those at work in the field, 
nor can it be the sole responsibility of lawmakers, 
regulators and bureaucrats73. 
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